| Identification | Back Directory | [Name]
ALK-4290 | [CAS]
1251528-23-0 | [Synonyms]
ALK-4290
BI-144807
4-Pyridinecarboxamide, 2-[[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]-4-piperidinyl]-5-oxo-2-pyrrolidinyl]carbonyl]amino]-N,N,6-trimethyl- | [Molecular Formula]
C27H34ClN5O3 | [MDL Number]
MFCD34470690 | [MOL File]
1251528-23-0.mol | [Molecular Weight]
512.04 |
| Chemical Properties | Back Directory | [Boiling point ]
743.8±60.0 °C(Predicted) | [density ]
1.288±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
11.94±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3]. | [IC 50]
CCR3: 3.2 nM (Ki) | [References]
[1] NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1.
[2] Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). May-Jun 2020; 9(3):250-259. DOI:10.1097/APO.0000000000000291
[3] Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|